Regeneron Pharmaceuticals, Inc. (REGN) Misses Q1 EPS by 36c

May 8, 2014 6:31 AM EDT

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings